Biomedtech News
Abivax announces the success of its oversubscribed capital increase
Abivax secures € 15M non-dilutive financing from Kreos Capital
CARMAT is granted € 13M in national innovation funding to conduct the EFICAS study in France
Abivax presents first-half 2020 financial results and operations update
Abivax Turns Away Suitors as Lead Drug Starts Covid-19 Tests
Abivax reports long-lasting two-year efficacy and safety data from ABX464 ulcerative colitis Phase 2A maintenance study
MEDEOR, Truffle Capital's new BioMedTech Fund, qualified by institutional investors through the Tibi committee
Abivax treats first patient in Phase 2B/3 ABX464 Covid-19 clinical trial
Abivax provides business update on most recent achievements and announces positive results of annual ordinary and extraordinary general meeting
Philippe Pouletty and Hartmut J. Ehrlich - ABIVAX - Covid-19 Quarantine
